sincalide and loxiglumide

sincalide has been researched along with loxiglumide* in 45 studies

Reviews

1 review(s) available for sincalide and loxiglumide

ArticleYear
Effect of cholecystokinin on gastric motility in humans.
    Annals of the New York Academy of Sciences, 1994, Mar-23, Volume: 713

    Gastric emptying after food ingestion is regulated by neural and hormonal factors. However, the relative contributions of each pathway is not yet clearly defined. The classic gut hormone CCK seems to be involved in the regulation of gastric emptying in humans. Experimental evidence is best for gastric emptying of liquid meals that release CCK from the duodenum: (1) CCK infused at postprandial plasma concentrations inhibits gastric emptying of a liquid and a semisolid meal. (2) Administration of the CCK antagonist loxiglumide significantly accelerated gastric emptying of a liquid mixed meal and a glucose meal. Discrepant results with the antagonist MK329 are difficult to explain considering the marked acceleration of gastric emptying rates by the specific and potent antagonist MK329 shown in several animal studies. Taken together, current information favors the conclusion, however, that CCK mainly controls gastric emptying of the liquid but not the solid components. Thus, CCK is involved in the physiologic regulation of gastric emptying and gastric motility in man. Blocking CCK-A receptors accelerates gastric emptying of liquid meals and abolishes the gastrocolonic reflex. Therefore, CCK may play a role as a common regulator of postprandial gallbladder contraction and pancreatic enzyme secretion as well as of gastric emptying rates under certain conditions. Such common control would optimize the nutrient-to-digestive juices concentration ratio. The importance of endogenous CCK on gastric emptying of solid meals, however, is poorly understood and remains to be defined. Only very limited information is available on gastric motility. Much more work has to be done before a clear concept can be developed.

    Topics: Benzodiazepinones; Cholecystokinin; Colon; Devazepide; Digestive System; Digestive System Physiological Phenomena; Duodenum; Gastric Emptying; Gastrointestinal Motility; Humans; Ileum; Infusions, Intravenous; Proglumide; Receptors, Cholecystokinin; Sincalide

1994

Trials

4 trial(s) available for sincalide and loxiglumide

ArticleYear
Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2000, Volume: 279, Issue:1

    Cholecystokinin (CCK) interacts with neural signals to induce satiety in several species, but the mechanisms are unclear. We therefore tested the hypothesis that alimentary CCK (CCK-A) receptors mediate the interaction of CCK with an appetizer on food intake in humans. CCK octapeptide (CCK-8, 0.75 microgram infused over 10 min) or saline (placebo) with concomitant infusions of saline (placebo) or loxiglumide, a specific CCK-A antagonist, was infused into 16 healthy men with use of a double-blind, four-period design. All subjects received a standard 400-ml appetizer (amounting to 154 kcal) but were free to eat and drink thereafter as much as they wished. The effect of these infusions on feelings of hunger and satiety and on food intake was quantified. CCK-8 induced a reduction in calorie intake (P < 0.05) compared with saline. Furthermore, a decrease in hunger feelings (P < 0.05, saline-CCK-8 vs. all other treatments) and an increase in fullness were observed. These effects were antagonized for hunger and fullness by loxiglumide. We conclude that CCK-8 interacts with an appetizer to modulate satiety in humans. These effects are mediated by CCK-A receptors.

    Topics: Adult; Cholecystokinin; Cross-Over Studies; Double-Blind Method; Eating; Energy Intake; Humans; Hunger; Infusions, Intravenous; Male; Proglumide; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Satiety Response; Sincalide

2000
Physiological role of cholecystokinin in gastroprotection in humans.
    The American journal of gastroenterology, 1998, Volume: 93, Issue:12

    Cholecystokinin (CCK) is able to protect gastric mucosa against acute injury in experimental animals but little is known about the role of this hormone in maintaining mucosal integrity in humans. This double-blind, placebo controlled study was performed in 16 healthy volunteers. It describes the effects of CCK-8 infused intravenously (i.v.) at physiological doses and endogenous CCK released by intraduodenal (i.d.) oleate on gastric mucosal damage, as brought about by ethanol without or with pretreatment with loxiglumide, a selective CCK-A receptor antagonist.. CCK-8 was infused i.v. 30 min before and throughout the study or i.d. oleate was instilled through a separate duodenal tube. Thirty minutes after the start of i.v. infusion of CCK or i.d. oleate instillation, 100 ml of 50% ethanol spray was applied to the gastric mucosa using an endoscope. Gastroscopy was performed and mucosal lesions were quantified using modified Lanza score. Gastric biopsies were taken from oxyntic mucosa for histological evaluation and gastric content was aspirated for radioimmunoassay of somatostatin.. In placebo-treated subjects ethanol caused endoscopic damage, with an average score of 2.8+/-0.2. Histologically, a widespread disruption of surface epithelium and deep hemorrhagic necrotic lesions were observed. Pretreatment with CCK or i.d. oleate markedly reduced the endoscopic lesion score to 0.7+/-0.1 and 0.3+/-0.1, respectively, and in both cases this reduction was accompanied by a significant rise in plasma CCK. Histologically, surface epithelium was still disrupted but deep necrotic lesions were absent. Gastric content collected before and after CCK or oleate showed a several-fold increase of luminally released somatostatin.. Pretreatment with loxiglumide abolished the protective effects of i.v. CCK-8 and i.d. oleate on mucosal lesions induced by ethanol and prevented the rise in intragastric somatostatin, but failed to affect the increments in plasma CCK. Endogenous CCK plays a physiological role in the maintenance of mucosal integrity. This occurs through activation of CCK-A receptors and is associated with an increased gastric luminal release of somatostatin.

    Topics: Adult; Cholecystokinin; Double-Blind Method; Duodenum; Ethanol; Gastric Mucosa; Gastroscopy; Hormone Antagonists; Humans; Injections, Intravenous; Male; Oleic Acid; Proglumide; Sincalide; Somatostatin; Stomach

1998
Cholecystokinin is a physiological regulator of gastric acid secretion in man.
    European journal of clinical investigation, 1994, Volume: 24, Issue:6

    CCK8 is a poor stimulant of gastric acid secretion in vivo, but is equipotent to gastrin-17 (G17) in in vitro systems. To further evaluate the role of cholecystokinin (CCK) in regulating acid output in humans, dose-response curves were constructed to CCK8 or G17 (6.4-800 pmol kg-1 per h) with and without a specific CCK-A receptor antagonist (loxiglumide). During loxiglumide infusion, G17-stimulated acid output was unchanged, whereas CCK8-stimulated secretion increased significantly. Gastric somatostatin-14 release increased fivefold with CCK8 alone, but was blocked with loxiglumide administration. These data suggest that CCK8 directly stimulates acid secretion by binding to a CCK-B/gastrin receptor on parietal cells, but at the same time inhibits acid responses by stimulating gastric somatostatin release to a CCK-A receptor-mediated pathway. To test which action of CCK is relevant under physiological circumstances, the effect of loxiglumide on fasting and post-prandial acidity was measured through continuous pH-metry. After eating, gastrin levels increased fourfold compared to controls with concomitant increases in acid secretion. These results suggest that post cibum, CCK is an inhibitor of acid secretion by regulating gastrin through local somatostatin; they support the hypothesis that CCK acts as an enterogastrone.

    Topics: Adult; Cholecystokinin; Dose-Response Relationship, Drug; Drug Interactions; Eating; Gastric Acid; Gastric Mucosa; Gastrins; Homeostasis; Hormones; Humans; Male; Middle Aged; Proglumide; Sincalide; Somatostatin

1994
Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia.
    Annals of the New York Academy of Sciences, 1994, Mar-23, Volume: 713

    Topics: Adult; Analysis of Variance; Double-Blind Method; Dyspepsia; Female; Gastric Emptying; Humans; Male; Middle Aged; Proglumide; Receptors, Cholecystokinin; Sincalide; Time Factors

1994

Other Studies

40 other study(ies) available for sincalide and loxiglumide

ArticleYear
Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes".
    Journal of medicinal chemistry, 2006, Apr-20, Volume: 49, Issue:8

    The interaction between the 1-47 N-terminus of the CCK(1)-R and the anthranilic acid based antagonists has been investigated by fluorescence spectroscopy. These antagonists interact with W39 of the N-terminal domain of the CCK(1)-R like that of the endogenous ligand CCK-8. This specific interaction was not found in other nonpeptide ligands of the CCK(1)-R. Conformational studies, using NMR and energy minimization procedures, have allowed formulation of a new hypothesis on the CCK(1)-R binding mode of the anthranilic antagonists.

    Topics: Animals; Binding, Competitive; Biological Assay; Humans; Indoles; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; ortho-Aminobenzoates; Pancreas; Proglumide; Protein Conformation; Rats; Receptor, Cholecystokinin A; Sincalide; Spectrometry, Fluorescence; Structure-Activity Relationship

2006
The effects of an essential fatty acid compound and a cholecystokinin-8 antagonist on iron deficiency induced anorexia and learning deficits.
    Nutritional neuroscience, 2004, Volume: 7, Issue:2

    Iron deficiency (ID) is among the most common nutritional diseases, causing deleterious effects that include decreases in cognitive function and weight loss. The ID also induces a reduction in the number and affinity of dopaminergic D2 receptors. The new finding that ID induces an increase in the pancreas cells, leads to the hypothesis that cholecystokinin-8 (CCK-8) is involved in the ID effects. The level of CCK-8 was higher among ID rats, compared with normal rats. The ID rats in our study were anorectic and performed poorly in learning tests (Morris water maze and passive avoidance learning). Essential fatty acids (EFA) mediate dopamine activity and have been found to rehabilitate learning deficits. Treatment with a fatty acid compound blocked both the learning deficits and the anorexia, while a CCK-8 antagonist was successful only against the anorectic effects.

    Topics: Animal Feed; Animals; Avoidance Learning; Cholecystokinin; Energy Intake; Hormone Antagonists; Iron Deficiencies; Islets of Langerhans; Linoleic Acid; Male; Motor Activity; Peptide Fragments; Proglumide; Rats; Rats, Long-Evans; Swimming; Weight Gain

2004
Differential mechanism and site of action of CCK on the pancreatic secretion and growth in rats.
    American journal of physiology. Gastrointestinal and liver physiology, 2003, Volume: 285, Issue:4

    Recent studies demonstrated that cholecystokinin (CCK) at physiological levels stimulates pancreatic enzyme secretion via a capsaicin-sensitive afferent vagal pathway. This study examined whether chemical ablation of afferent vagal fibers influences pancreatic growth and secretion in rats. Bilateral subdiaphragmatic vagal trunks were exposed, and capsaicin solution was applied. Pancreatic wet weight and pancreatic secretion and growth in response to endogenous and exogenous CCK were examined 7 days after capsaicin treatment. Perivagal application of capsaicin increased plasma CCK levels and significantly increased pancreatic wet weight compared with those in the control rats. Oral administration of CCK-1 receptor antagonist loxiglumide prevented the increase in pancreatic wet weight after capsaicin treatment. In addition, continuous intraduodenal infusion of trypsin prevented the increase in plasma CCK levels and pancreatic wet weight after capsaicin treatment. There were no significant differences in the expression levels of CCK-1 receptor mRNA and protein in the pancreas in capsaicin-treated and control rats. Intraduodenal administration of camostat or intravenous infusion of CCK-8 stimulated pancreatic secretion in control rats but not in capsaicin-treated rats. In contrast, repeated oral administrations of camostat or intraperitoneal injections of CCK-8 significantly increased pancreatic wet weight in both capsaicin-treated and control rats. Present results suggest that perivagal application of capsaicin stimulates pancreatic growth via an increase in endogenous CCK and that exogenous and endogenous CCK stimulate pancreatic growth not via vagal afferent fibers but directly in rats.

    Topics: Afferent Pathways; Amylases; Animals; Capsaicin; Cholecystokinin; Duodenum; Eating; Lipase; Male; Organ Size; Pancreas; Proglumide; Rats; Rats, Wistar; Sincalide; Trypsin; Trypsinogen; Vagotomy; Vagus Nerve

2003
Pharmacological and molecular characterization of muscular cholecystokinin receptors in the human lower oesophageal sphincter.
    Neurogastroenterology and motility, 2000, Volume: 12, Issue:6

    In vitro cholecystokinin (CCK) contracts the human lower oesophageal sphincter by stimulating muscular receptors. The aim of this study was to characterize the muscular CCK receptor subtypes in the human lower oesophageal sphincter. Twenty-five circular strips from six patients were studied. RNA was extracted, reverse transcribed, and cDNAs were amplified with primers for human CCK-A and B receptors. The potency of the contraction induced by CCK-8, desulphated CCK-8, and gastrin-I, and the effect of the CCK-A (loxiglumide and SR 27897) and the CCK-B (YM022 and L-365 260) specific receptor antagonists were compared. Both CCK-A and CCK-B receptor mRNAs were found in functional lower oesophageal sphincter strips. The potency of the CCK-8 concentration-dependent contraction was two and three orders of magnitude higher than that of desulphated CCK-8 and gastrin-I, respectively. The CCK-8-induced contraction was blocked by the CCK-A receptor antagonists loxiglumide (IC50 11 micromol L-1) and SR 27897 (IC50 74 nmol L-1) but not by CCK-B receptor antagonists (1 micromol L-1). Our data suggest that, although the human lower oesophageal sphincter expresses both CCK-A and CCK-B receptors, the contractile effect of CCK-8 on the circular muscle is mainly due to the activation of CCK-A receptors.

    Topics: Adult; Aged; Benzodiazepines; Benzodiazepinones; Esophagogastric Junction; Female; Gastric Emptying; Gastrins; Gastrointestinal Agents; Gene Expression; Hormone Antagonists; Humans; In Vitro Techniques; Indoleacetic Acids; Male; Middle Aged; Phenylurea Compounds; Proglumide; Receptors, Cholecystokinin; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sincalide; Thiazoles

2000
Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
    Pancreas, 1999, Volume: 18, Issue:2

    We investigated the pharmacologic characteristics of a newly developed benzodiazepine derivative (S)-(-)-N-[2,3-dihydro-2-oxo-5-phenyl-1-[(1H-tetrazol-5-yl)methyl] -1H-1,4-benzodiazepine-3-yl]-2-indolecarboxamide (TS-941), a cholecystokinin type A (CCK-A)-receptor antagonist, in the isolated rat pancreatic acini and compared with those of well-known CCK-A-receptor antagonists, devazepide and loxiglumide. TS-941 inhibited CCK-8-stimulated amylase release concentration dependently, as did devazepide and loxiglumide, with a half-maximal inhibition (IC50) at 78.6 +/- 10.3 nM. TS-941 was approximately 23 times less potent than devazepide (IC50, 3.4 +/- 0.3 nM), but was 50 times more potent than loxiglumide (IC50, 3,966 +/- 544 nM) in inhibiting 100 pM CCK-8-stimulated amylase release from rat pancreatic acini. TS-941 had a fivefold lower selectivity than devazepide for pancreatic CCK (CCK-A) over brain CCK (CCK-B) receptors but fourfold greater than loxiglumide when IC50 values for inhibition of [125I]CCK-8 binding in isolated acini and cerebral cortex were compared. The antagonism produced by TS-941 was specific for CCK in that the effects of other receptor secretagogues or agents bypassing receptors were not altered. TS-941 caused a parallel rightward shift of the entire dose-response curve for CCK-8-stimulated amylase release without altering the maximal increase, as did devazepide and loxiglumide. TS-941, whether added at the beginning or 20 min after the CCK-8 stimulation, inhibited amylase release. TS-941 caused a concentration-dependent residual inhibition of the action of CCK-8. The acini, once incubated with a high concentration of TS-941 (10 microM; 127 times IC50) for 30 min, was 10-fold less sensitive to CCK-8 than the acini preincubated without TS-941, whereas the sensitivity and the responsiveness to CCK-8 stimulation of those incubated with a low concentration of TS-941 (1.0 microM) were similar to the control acini. These results indicate that TS-941 is a potent, competitive, and selective CCK-A receptor antagonist for the pancreas.

    Topics: Amylases; Animals; Benzodiazepines; Binding, Competitive; Cell Membrane; Cell Survival; Cells, Cultured; Cerebral Cortex; Devazepide; Dose-Response Relationship, Drug; Hormone Antagonists; Male; Pancreas; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide

1999
Acceleration of ulcer healing by cholecystokinin (CCK): role of CCK-A receptors, somatostatin, nitric oxide and sensory nerves.
    Regulatory peptides, 1999, Jun-30, Volume: 82, Issue:1-3

    CCK exhibits a potent cytoprotective activity against acute gastric lesions, but its role in ulcer healing has been little examined. In this study we determined whether exogenous CCK or endogenously released CCK by camostate, an inhibitor of luminal proteases, or by the diversion of pancreatico-biliary secretion from the duodenum, could affect ulcer healing. In addition, the effects of antagonism of CCK-A receptors (by loxiglumide, LOX) or CCK-B receptors (by L-365,260), an inhibition of NO-synthase by N(G)-nitro-L-arginine (L-NNA), or sensory denervation by large neurotoxic dose of capsaicin on CCK-induced ulcer healing were examined. Gastric ulcers were produced by serosal application of acetic acid and animals were sacrificed 9 days after ulcer induction. The area of ulcers and blood flow at the ulcer area were determined. Plasma levels of gastrin and CCK and luminal somatostatin were measured by RIA and mucosal biopsy samples were taken for histological evaluation and measurement of DNA synthesis. CCK given s.c. reduced dose dependently the ulcer area; the threshold dose of CCK being 1 nmol/kg and the dose inhibiting this area by 50% being 5 nmol/kg. This healing effect of CCK was accompanied by a significant increase in the GBF at ulcer margin and the rise in luminal NO production, plasma gastrin level and DNA synthesis. Concurrent treatment with LOX, completely abolished the CCK-8-induced acceleration of the ulcer healing and the rise in the GBF at the ulcer margin, whereas L-365,260 remained without any influence. Treatment with camostate or diversion of pancreatic juice that raised plasma CCK level to that observed with administration of CCK-8, also accelerated ulcer healing and this effect was also attenuated by LOX but not by L-365,260. Inhibition of NO-synthase by L-NNA significantly delayed ulcer healing and reversed the CCK-8 induced acceleration of ulcer healing, hyperemia at the ulcer margin and luminal NO release, and these effects were restored by the addition to L-NNA of L-arginine but not D-arginine. Capsaicin denervation attenuated CCK-induced ulcer healing, and the accompanying rise in the GBF at the ulcer margin and decreased plasma gastrin and luminal release of somatostatin when compared to those in rats with intact sensory nerves. Detectable signals for CCK-A and B receptor mRNAs as well as for cNOS mRNA expression were recorded by RT-PCR in the vehicle control gastric mucosa. The expression of CCK-A receptor mRNA and cNOS mRNA wa

    Topics: Animals; Cholecystokinin; DNA Replication; Dopamine Agents; Esters; Gabexate; Gastric Mucosa; Gastrins; Guanidines; Hormone Antagonists; Male; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Pancreatin; Proglumide; Protease Inhibitors; Rats; Rats, Wistar; Receptors, Cholecystokinin; Regional Blood Flow; RNA, Messenger; Sensory Receptor Cells; Sincalide; Somatostatin; Stomach; Stomach Ulcer

1999
CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
    Pancreas, 1998, Volume: 16, Issue:2

    We examined the effects of treatment with cholecystokinin (CCK) octapeptide (CCK-8) and the CCK receptor antagonist loxiglumide on the recovery of exocrine pancreas in post-acute pancreatitic rats. Acute pancreatitis was induced in rats by intravenous infusion of 20 microg/kg/h cerulein for 4 h. At 24 h after the start of cerulein infusion, rats were divided into nine treatment groups: oral administration of saline (control), or oral administration of 10 or 50 mg/kg body weight loxiglumide twice daily for the first 3 days, followed by saline administration (Loxi-1 and Loxi-2), 10 or 50 mg/kg body weight loxiglumide twice daily for 6 days (Loxi-3 and Loxi-4), oral administration of saline or 10 or 50 mg/kg body weight loxiglumide twice daily for the first 3 days, followed by subcutaneous injection of 2.5 microg/kg body weight CCK-8 twice daily for the next 3 days (CCK-1, CCK-2, and CCK-3), and subcutaneous injection of 2.5 microg/kg body weight CCK-8 twice daily for 6 days (CCK-4). Pancreatic wet weight and biochemical changes were evaluated on day 8 at 12 h after the last treatment. Treatment with loxiglumide (Loxi-3 and Loxi-4) or CCK-8 for 6 days (CCK-4) or with a high dose of loxiglumide for the first 3 days (Loxi-2) significantly suppressed the recovery of pancreatic weight and DNA content compared to saline treatment or to the untreated normal control rats. However, when loxiglumide treatment was followed by 3 days of CCK-8 injections (CCK-2 and CCK-3), pancreatic protein and DNA content recovered to levels comparable to or above the control levels. The most remarkable increase in enzyme content was obtained in postpancreatitic rats treated with high-dose loxiglumide for the first 3 days, followed by CCK-8 injection (CCK-3). On the other hand, 6 days of CCK-8 treatment (CCK-4) had no significant influences on pancreatic enzyme contents. These results suggest that the most favorable strategy for the treatment of acute pancreatitis is to give high-dose loxiglumide during the early stage for only a short period, followed by CCK-8 administration.

    Topics: Acute Disease; Amylases; Animals; Ceruletide; Cholecystokinin; DNA; Hormone Antagonists; Lipase; Male; Organ Size; Pancreas; Pancreatitis; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Regeneration; Sincalide; Trypsin

1998
Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors.
    Gastroenterology, 1998, Volume: 115, Issue:3

    Exogenous cholecystokinin (CCK) decreases lower esophageal sphincter (LES) pressure and increases transient LES relaxations (TLESRs) in humans. The aims of this study were to determine whether endogenous CCK increases gastroesophageal reflux in humans and whether this is a direct effect on the LES.. Esophageal pH, LES pressure, and gallbladder volume were measured in 8 healthy volunteers after ingestion of a 181-kcal meal alone or adding 12 g cholestyramine to increase endogenous CCK release. In 7 additional volunteers, the effect of cholestyramine was studied during intravenous perfusion of saline or the CCK-A receptor antagonist loxiglumide. In circular LES strips from 9 transplant donors, we measured the effect of CCK-8 (10(-11) to 3 x 10(-8) mol/L) on basal tension and on electrical field-induced relaxation.. Cholestyramine increased gallbladder emptying, reflux episodes, TLESRs, and time of esophageal pH of <4. Loxiglumide inhibited postprandial gallbladder emptying, reflux episodes, TLESRs, and time of pH of <4 and prevented the decrease in LES pressure induced by cholestyramine. In vitro, CCK-8 contracted LES strips through a tetrodotoxin-insensitive pathway but did not modify electrical field-induced LES relaxations.. Endogenous CCK enhances postprandial gastroesophageal reflux in humans by increasing the rate of TLESRs and reduces postprandial LES pressure. These actions seem mediated by extrasphincteric CCK-A receptors that override a direct contractile effect of CCK on the LES muscle.

    Topics: Adult; Cholecystokinin; Cholestyramine Resin; Eating; Electric Stimulation; Esophagogastric Junction; Esophagus; Gallbladder; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Proglumide; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Sincalide

1998
Involvement of endogenous cholecystokinin and somatostatin in gastroprotection induced by intraduodenal fat.
    Journal of clinical gastroenterology, 1998, Volume: 27 Suppl 1

    Duodenal fat such as oleate is known to influence gut functions by release of cholecystokinin (CCK), but the contribution of CCK endogenously released by duodenal fat or by diversion of pancreatic juice from the duodenum in the mechanism of mucosal integrity and gastroprotection has been little studied. This study was designed to compare the effect of CCK-8 and intraduodenal (i.d.) instillation of sodium oleate, or diversion of the pancreatic biliary secretions that are known to release CCK, on the gastric mucosal lesions induced by topical application of 100% ethanol or acidified aspirin (ASA) in rats with or without the pretreatment with a CCK-A receptor antagonist, loxiglumide, or with L-365,260 to block CCK-B receptors. In addition, the effect of suppression of prostaglandin (PG) biosynthesis by indomethacin (5 mg/kg i.p.), inhibition of nitric oxide (NO)-synthase by L-NAME (5 mg/kg i.v.), or blockade of sensory nerves by capsaicin (125 mg/kg s.c.) on the protective activity of sodium oleate was determined. Sodium oleate (50-200 mM i.d.), or diversion of pancreatic juice from the duodenum for 3 h that produced significant rise in plasma CCK levels, significantly reduced gastric lesions induced by 100% ethanol to an extent similar to that induced by exogenous CCK-8 (5 nmol/kg s.c.). The protective effect of oleate or diversion of pancreatic juice was accompanied by an increase in gastric blood flow (GBF). Both protection and accompanying hyperemia were completely abolished by blockade of CCK-A receptors with loxiglumide, whereas L-365,260, an antagonist of CCK-B receptors, had no effect. Oleate given i.d. significantly attenuated acidified ASA-induced gastric lesions and gastric secretion while increasing the luminal concentration of somatostatin. These effects were significantly reduced by loxiglumide but not by L-365,260. In contrast, CCK-8, which stimulated gastric acid secretion, failed to affect the lesions induced by acidified ASA and the decrease in the GBF produced by this ulcerogen. Indomethacin, which suppressed PG generation by approximately 90%, failed to influence the protective activity of oleate or CCK-8 against ethanol-induced lesions, whereas L-NAME, vagotomy, or sensory denervation significantly attenuated this protection and accompanying hyperemia. Addition to L-NAME of L-arginine, but not D-arginine, restored the protective and hyperemic effects of CCK-8 and duodenal oleate against gastric lesions induced by ethanol or acidified ASA

    Topics: Animals; Capsaicin; Cholecystokinin; Denervation; Dinoprostone; Dopamine Agents; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Hormone Antagonists; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Oleic Acid; Pepsin A; Proglumide; Rats; Rats, Wistar; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Sincalide; Somatostatin; Stomach Ulcer; Vagotomy

1998
Impairment of hepatic transport processes in perfused rat liver by the specific CCK receptor antagonist loxiglumide.
    Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, 1997, Volume: 197, Issue:3

    The specific cholecystokinin (CCK) receptor antagonist loxiglumide has been used in several human and animal studies to investigate the role of CCK in gastrointestinal physiology. In the present study, the interference of this CCK receptor antagonist with hepatic transport processes was characterized in the perfused rat liver. Indocyanine green, an organic dye which is secreted into bile without being metabolized, was taken up in control experiments at a rate of 68.1 +/- 7.7%. The CCK receptor antagonist lowered the extraction to 0.5 +/- 2.6% (P < 0.001). The compound diminished the hepatic extraction of CCK-8 from 90.95 +/- 2.60% to 4.90 +/- 1.95% (P < 0.001) and of gastrin from 22.2 +/- 1.1% to 8.2 +/- 1.9% (P < 0.001). The hepatic extraction of lidocaine, which is metabolized by the cytochrome P450 system, was only slightly altered. For leukotrienes and taurocholate, the rate-limiting step for transport into bile is secretion across the canalicular membrane; the hepatic extraction of leukotriene D4 was markedly diminished by loxiglumide whereas the transport of taurocholate was only slightly inhibited. The present study demonstrates that the specific CCK receptor antagonist loxiglumide diminished the hepatic extraction of various substances, including peptides and organic anions. It did not interfere with the cytochrome P450 system. The pronounced reduction of hepatic uptake of indocyanine green and leukotriene may be due to an interference with the transport system of these substances in the liver.

    Topics: Animals; Bile; Biological Transport; Cholagogues and Choleretics; Gastrins; Hormone Antagonists; Indocyanine Green; Leukotriene D4; Liver; Male; Portal Vein; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide; Taurocholic Acid

1997
Endogenous CCK inhibits colonic contractions in unrestrained conscious rats.
    Regulatory peptides, 1997, Oct-31, Volume: 72, Issue:2-3

    As cholecystokinin octapeptide (CCK-OP) and feeding have been reported to relax the circular muscle contractions of the proximal colon in unrestrained conscious rats under fasting conditions, the, action of cholecystokinin, released after duodenal infusion of a low residual diet of clinimeal, was studied on the motor activity of the proximal colon in unrestrained conscious rats. We used an implantable telemetry system with a miniature strain gauge force transducer introduced into the rat proximal colon. By using a specific radioimmunoassay system for CCK, plasma levels of CCK before and after duodenal infusion of clinimeal (0.5, 1.0, 2.0 ml) were determined at 0, 5, 10, 20, 30, 60 min in the portal blood. The clinimeal infusion caused a significant increase in CCK levels of the portal plasma during 5 and 30 min. This increase was in a dose-dependent manner. In accordance with this increase in plasma CCK, the motor activity of the proximal circular muscle was suppressed significantly. A bolus injection of the CCK A receptor antagonist, loxiglumide, CR 1505 (0.1, 0.5 and 1.0 mg/kg ip), prior to clinimeal blocked the inhibitory action of CCK on the motor activity in a concentration-dependent manner. These data suggest that endogenous CCK released by a residual diet is involved in the mechanism of inhibition of motor activity in the proximal colon.

    Topics: Animal Feed; Animals; Colon; Dose-Response Relationship, Drug; Duodenum; Eating; Fasting; Gastrointestinal Motility; Hormone Antagonists; Intubation, Gastrointestinal; Male; Muscle Contraction; Muscle, Smooth; Portal Vein; Proglumide; Radioimmunoassay; Rats; Rats, Wistar; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Reference Values; Sincalide; Telemetry; Transducers

1997
Luminal cholecystokinin and gastrin cause gallbladder contraction.
    The Journal of surgical research, 1996, Volume: 62, Issue:2

    Cholecystokinin-8 placed in the gallbladder lumen causes gallbladder contraction by a neurally mediated, tetrodotoxin-sensitive mechanism. We wished to determine whether other cholecystokinin-like peptides in the gallbladder lumen cause contraction and whether this response is inhibited by cholecystokinin-receptor antagonists. In this study, we measured gallbladder contraction induced by cholecystokinin-like peptides or by hepatic bile placed in the gallbladder lumen. Isolated gallbladders were suspended in an organ bath while luminal hormones were infused. Gallbladder contraction was measured by continuous monitoring of luminal pressure. Cholecystokinin-8, cholecystokinin-5, and gastrin-17 caused dose-related gallbladder contraction with similar potency when placed in the lumen. Each stimulated 70-80% maximal contraction at a luminal concentration of 10(-6) M. Cholecystokinin-receptor antagonists CR1409 and loxiglumide partially inhibited contraction caused by luminal cholecystokinin-8. Bile from fed animals, but not from fasted animals, stimulated gallbladder contraction to 36 +/- 4% of maximal when placed in the gallbladder lumen. We conclude that cholecystokinin and gastrin peptides in the gallbladder lumen cause contraction. This may be mediated through receptors of the cholecystokinin-B type, possibly on intrinsic nerves. Bile from fed animals also contains substances that stimulate gallbladder contraction when bile is placed in the gallbladder lumen. These findings suggest intrinsic nerves participate in the postprandial gallbladder response to cholecystokinin.

    Topics: Animals; Bile; Cholecystokinin; Female; Gallbladder; Gastrins; Guinea Pigs; Hormone Antagonists; In Vitro Techniques; Muscle Contraction; Pentagastrin; Proglumide; Receptors, Cholecystokinin; Sincalide

1996
Effects of cholecystokinin and carbachol on membrane fluidity in pancreatic acini.
    Digestive diseases and sciences, 1996, Volume: 41, Issue:7

    The effects of pancreatic secretagogues on the membrane fluidity of pancreatic acini were investigated using 1-[4-(trimethylammonium)phenyl]-6-phenyl-1,3,5-hexatriene iodide as a probe. Two kinds of pancreatic secretagogues, one category of which induces acute pancreatitis (cholecystokinin and carbachol) and another which does not induce acute pancreatitis (bombesin, CCK-JMV-180, and secretin), as well as lecithin were used to investigate the effect of changes in membrane fluidity of acini. Our study revealed that the membrane fluidity of the pancreatic acini was unaffected by a physiological dose (10(-11) M) of cholecystokinin. However, stimulation with a supramaximal dose of cholecystokinin (10(-8) M) increased membrane fluidity markedly within 20 min. Membrane fluidity increased dose-dependently with increasing CCK stimulation. A supramaximal dose of cholecystokinin also induced bleb formation and increased LDH release. These phenomena were blocked by simultaneous incubation with CR1505 (Loxiglumide), a potent antagonist of peripheral cholecystokinin receptors. A supramaximal dose of carbachol (10(-3) M) also induced increases in the membrane fluidity. Pancreatic secretagogues that do not induce acute pancreatitis did not induce alterations in membrane fluidity. Lecithin increased both membrane fluidity and LDH release. These observations suggest that this increase in membrane fluidity of the pancreatic acini may be related to membrane alteration and to functional damage of the acini. These observations [correction of observation] can serve as a window to detect the development of acute pancreatitis at an early stage.

    Topics: Animals; Bombesin; Carbachol; Cholecystokinin; Dose-Response Relationship, Drug; Hormone Antagonists; L-Lactate Dehydrogenase; Male; Membrane Fluidity; Pancreas; Pancreatitis; Phosphatidylcholines; Proglumide; Rats; Rats, Wistar; Secretin; Sincalide

1996
Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
    British journal of pharmacology, 1996, Volume: 117, Issue:7

    1. The pharmacological characteristics of a newly developed serine derivative (R)-1-[3-(3-carboxypyridine-2-yl) thio-2-(indol-2-yl)carbonylamino]propionyl-4-diphenylmethyl- piperazine (TP-680), a cholecystokinin type A (CCKA) receptor antagonist, were studied and compared with those of MK-329 and loxiglumide. 2. TP-680 showed approximately 2 and 22 times greater selectivity for peripheral CCKA receptors relative to brain CCK (CCKB) receptors than MK-329 and loxiglumide, respectively, when IC50 values for inhibition of [125I]-CCK-8 binding in isolated acini and cerebral cortex were compared. 3. TP-680 was approximately 17 times less potent than MK-329, but was 106 times more potent than loxiglumide in inhibiting 100 pM CCK-8-stimulated amylase release from rat pancreatic acini. The antagonism produced by TP-680 was specific for CCK in that the effects of other receptor secretagogues or agents bypassing receptors were not altered. 4. TP-680 caused a parallel rightward shift of the dose-response curve for CCK-8-stimulated amylase release as did MK-329 and loxiglumide. However, in contrast to MK-329 and loxiglumide, TP-680 suppressed the maximal responses of CCK-8-induced amylase release in a concentration-dependent fashion, indicating that TP-680 is an unsurmountable antagonist. 5. Repeated washing of acini after a 30 min treatment with TP-680 restored the responsiveness but not the sensitivity, causing a residual inhibition on the action of CCK-8. 6. The addition of loxiglumide prior to or together with application of TP-680 protected CCK receptors from unsurmountable and irreversible antagonism by TP-680. 7. Our results indicate that TP-680 is a potent and the most selective CCKA receptor antagonist for the pancreas reported to date.

    Topics: Amylases; Animals; Benzodiazepinones; Binding, Competitive; Cerebral Cortex; Cysteine; Devazepide; In Vitro Techniques; Intracellular Membranes; Male; Niacin; Pancreas; Proglumide; Rats; Rats, Wistar; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Sincalide

1996
Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.
    Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:3

    Clear definition of the role of CCK in the physiology of gastric motor activity has been long hampered by the lack of specific and potent nonpeptide antagonists of CCK-receptors. The availability of such compounds has stimulated a broad array of investigations into the physiological actions of this hormone and to examine its putative role in certain diseases.. The effect of two recently developed CCK-receptor antagonists, namely dexloxiglumide and spiroglumide, on gastric emptying and secretion as well as their selectivity towards CCKA- and CCKB-receptors in vivo was studied in the rat.. Gastric emptying was quantified by using a liquid noncaloric meal labelled with phenol red. Acid secretion was measured by titration in conscious rats.. The putative CCKA-antagonist, dexloxiglumide, administered by intravenous route, was able to inhibit CCK-8-induced delay of gastric emptying in a dose-dependent fashion, with an ID50 (95% CL) of 1.14 (0.84-1.53) mg/kg. Similarly, the putative CCKB-gastrin-antagonist, spiroglumide, proved to be capable of inhibiting dose-dependently pentagastrin-induced acid hypersecretion, its ID50 being 20.1 (8.67-46.4) mg/kg. On the other hand, dexloxiglumide, at doses able to almost completely block CCKA mediated effects (i.e. delay of gastric emptying), was ineffective against pentagastrin-induced acid hypersecretion. Similarly, spiroglumide, at doses which inhibit by 55% CCKB-gastrin mediated effects (i.e. acid secretion) was inactive when tested against CCK-8 induced delay of gastric emptying.. These results demonstrate in vivo that dexloxiglumide is a selective antagonist for CCKA-receptors whereas spiroglumide is selective for CCKB-gastrin-receptors. These compounds are therefore useful tools for discriminating between different subclasses of CCK-receptors in vivo and might have a therapeutic potential in motility or acid-related disorders.

    Topics: Animals; Dose-Response Relationship, Drug; Gastric Acid; Gastric Emptying; Hormone Antagonists; Keto Acids; Male; Pentagastrin; Pentanoic Acids; Proglumide; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Sincalide; Spiro Compounds

1996
Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
    European journal of pharmacology, 1996, May-23, Volume: 304, Issue:1-3

    The pharmacological profile of a new CCKA receptor antagonist, T-0632 [sodium (S)-3-[1-(2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinyl)-carbonyl] amino-6-methoxy-2-oxo-1-H-indole]propanoate], was examined in in vitro studies and compared with those of L-364,718 [3S(-)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1, 4-benzodiazepine-3-yl)-1H-indole-2-carboxamide] and loxiglumide [D,L-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylam ino)-5- oxopentanoic acid]. T-0632 inhibited the specific binding of [125I]CCK-8 to rat pancreatic CCKA receptor in a concentration-dependent and competitive manner. The Ki value of T-0632 for the CCKA receptor was estimated to be 0.24 nM, which was 23 000-fold less than the Ki value (5600 nM) for guinea pig CCKB receptor. L-364,718 and loxiglumide were 1500- and 64-fold selective for CCKA over CCKB receptor, respectively. T-0632, L-364,718 and loxiglumide inhibited CCK-8 (100 pM)-stimulated amylase release from rat pancreatic acini in a concentration-dependent manner with IC50 values of 5.0 nM, 5.0 nM and 3.0 microM, respectively. In the isolated rabbit gallbladder smooth muscle, T-0632 and loxiglumide competitively inhibited CCK-8-induced contraction with pA2 values of 8.5 and 7.0, respectively. However, L-364,718 showed an apparent non-competitive antagonism. The IC50 values of T-0632, L-364,718 and loxiglumide for CCK-8 (30 nM)-induced contraction were 31 nM, 4.9 nM and 1300 nM, respectively. The inhibitory effects of T-0632 and loxiglumide in gallbladder smooth muscle were readily reversible, but L-364,718 showed a long-lasting inhibition. These results suggest that T-0632 is a potent, reversible and more selective CCKA receptor antagonist compared with L-364,718 and loxiglumide.

    Topics: Amylases; Animals; Benzodiazepinones; Binding, Competitive; Brain; Cell Membrane; Devazepide; Gallbladder; Guinea Pigs; Hormone Antagonists; In Vitro Techniques; Indoles; Male; Muscle Contraction; Muscle, Smooth; Pancreas; Proglumide; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Sincalide

1996
Comparison of the effects of two cholecystokinin-receptor antagonists, loxiglumide and L-364,718, on the pancreatic secretory response to intraduodenal tryptophan in dogs.
    Scandinavian journal of gastroenterology, 1996, Volume: 31, Issue:7

    The aim of the study was to compare the effects of the cholecystokinin (CCK)-receptor antagonists loxiglumide and L-364, 718 on the endogenously stimulated pancreatic exocrine secretion.. In six conscious dogs with chronic gastric and pancreatic fistulas we compared the action of different doses of loxiglumide (2.5 to 10.0 mg/kg/h) and L-364, 718 (0.025 to 0.1 mg/kg/h) on the pancreatic secretory response to intraduodenal perfusion of graded loads of tryptophan (0.37-10.0 mmol/ h), given against a background of secretin (20.5 pmol/kg/h intravenously).. Both loxiglumide and L-364, 718 inhibited the secretin-stimulated pancreatic bicarbonate output by up to 47% and 48%, respectively. The pancreatic protein output during secretin was significantly inhibited by all doses of L-364,718 (by 65% to 82%) but not by loxiglumide. All doses of loxiglumide and L-364, 718 abolished the 180-min integrated bicarbonate response to tryptophan. The two higher doses of loxiglumide (5.0-10.0 mg/kg/h) and L-364,718 (0.05-0.1 mg/kg/h) significantly decreased the 180-min integrated response to tryptophan by 59% and 79% (loxiglumide) and by 72% and 97% (L-364, 718). The plasma CCK-like immunoreactivity basally and in response to tryptophan was not significantly altered by loxiglumide or L-364, 718.. These findings indicate that in dogs 1) the pancreatic bicarbonate response to secretin is augmented by the hormone CCK; 2) L-364, 718 but not loxiglumide decreases pancreatic protein output during secretin; 3) endogenous released CCK is involved in the pancreatic bicarbonate response and is a major mediator of pancreatic protein response to intraduodenal tryptophan; and 4) the release of CCK by intraduodenal tryptophan is not influenced by loxiglumide and L-364, 718.

    Topics: Animals; Benzodiazepinones; Bicarbonates; Cholecystokinin; Devazepide; Dogs; Duodenum; Female; Male; Pancreas; Perfusion; Proglumide; Receptors, Cholecystokinin; Secretin; Sincalide; Tryptophan

1996
Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    European journal of pharmacology, 1996, Sep-26, Volume: 312, Issue:2

    The pharmacological profile of a new CCKA receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], was examined in in vivo studies and compared with those of L-364, 718 [3S(-)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1, 4-benzodiazepine-3-yl)-1 H-indole-2-carboxamide] and loxiglumide [D.L-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylam ino)-5- oxopentanoic acid]. In rats, intravenously administered T-0632, L-364,718 and loxiglumide dose dependently inhibited cholecystokinin octapeptide (CCK-8)-stimulated pancreatic exocrine secretion with estimated ED50 values of 0.025, 0.016 and 1.8 mg/kg, respectively. The ED50 values for intraduodenal administration of these compounds were 0.040, 0.26 and 3.0 mg/kg, respectively. In mice, orally administered T-0632 prevented caerulein-induced pancreatitis, CCK-8-induced inhibition of gastric emptying and CCK-8-induced gallbladder emptying in dose-dependent manners with ED50 values of 0.028, 0.04, and 0.12 mg/kg, respectively. The effect of T-0632 for caerulein-induced pancreatitis was 4-fold more potent than that for gallbladder emptying. In contrast, the effects of L-364,718 and loxiglumide for caerulein-induced pancreatitis were 2-4-fold weaker than those for gallbladder emptying. In dogs, T-0632 and loxiglumide maximally inhibited CCK-8-stimulated pancreatic amylase secretion at doses of 0.01 and 10 mg/kg, respectively. At these doses, the effect of T-0632 on CCK-8-induced increase in the gallbladder intraluminal pressure was weaker than that of loxiglumide. These results suggest that T-0632 has a potent antagonistic action on CCKA receptors in several animal species and the effects of T-0632 are more selective for the pancreas over the gallbladder compared with L-364,718 and loxiglumide.

    Topics: Animals; Benzodiazepinones; Ceruletide; Devazepide; Dogs; Female; Gastric Emptying; Indoles; Male; Pancreas; Pancreatitis; Pregnancy; Proglumide; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Sincalide

1996
Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines.
    FEBS letters, 1996, Apr-01, Volume: 383, Issue:3

    Recently, cholecystokinin has been reported to be important in regulating the growth of pancreatic cancer. We investigated the effect of loxiglumide (LXG), a cholecystokinin receptor antagonist, on the invasiveness of two human pancreatic cancer cell lines. Cells were treated with LXG for 24 h, and examined in the invasion assay. The expression and activity of MMP-9 in supernatants from cancer cells were analyzed by Western blotting and zymogram. Interestingly, the invasiveness of cancer cells and expression of MMP-9 were decreased by LXG in a dose-dependent manner. LXG may be a useful therapeutic agent against pancreatic cancer.

    Topics: Blotting, Western; Cell Line; Collagenases; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Gelatin; Hormone Antagonists; Humans; Kinetics; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Pancreatic Neoplasms; Proglumide; Sincalide; Tumor Cells, Cultured

1996
Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats.
    Pancreas, 1995, Volume: 10, Issue:3

    The effect of a new cholecystokinin (CCK)-A receptor antagonist, FK480, developed in Japan, on pancreatic exocrine secretion stimulated by exogenous CCK and intraduodenal casein was investigated in vivo when administered to anesthetized rats intraduodenally, and its CCK antagonistic activity was compared with that of CR 1505. Intraduodenal administration of FK480 at graded doses of 0.0016-1.0 mg/kg-h produced dose-dependent inhibition of pancreatic juice volume and amylase output stimulated by intravenous infusion of CCK-8 at a dose of 0.06 micrograms/kg-h. The half-maximal inhibitory dose (ID50) of FK480 for CCK-8-stimulated amylase secretion was 0.025 mg/kg-h, whereas the ID50 of CR 1505 was 5.2 mg/kg-h, indicating that FK480 is 208 times more potent than CR 1505. Moreover, intraduodenal FK480 (0.2 mg/kg-h) significantly suppressed pancreatic juice volume and amylase output augmented by intraduodenal infusion of casein (400 mg/h). It is concluded that FK480 administered intraduodenally has a significant, potent inhibitory action on the exocrine pancreas stimulated by exogenous CCK and intraduodenal casein.

    Topics: Amylases; Animals; Benzodiazepinones; Caseins; Duodenum; Indoles; Male; Pancreas; Pancreatic Juice; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide

1995
Regulation of gene expression of pancreatic secretory trypsin inhibitor-61 and -56 by bile and pancreatic juice in rats.
    Pancreas, 1995, Volume: 11, Issue:3

    The rat possesses two pancreatic secretory trypsin inhibitors (PSTI-61 and -56). PSTI-61 has been known to stimulate cholecystokinin (CCK) release, whereas PSTI-56 did not. Both PSTIs are synthesized in the pancreatic acinar cells. CCK has a trophic effect on pancreatic acinar cells, and the exclusion of bile-pancreatic juice from the intestine has been known to be a most potent stimulator of CCK release. In the present study, we examined whether the mRNA levels of PSTI-61 and -56 produced by bile-pancreatic juice diversion were different from each other and compared the changes in CCK mRNA levels in the small intestinal mucosa and the plasma and intestinal CCK concentrations. Male Wistar rats were prepared with internal fistula and bile-pancreatic juice was excluded from the proximal intestine, being introduced into the distal ileum. Rats were sacrificed 1, 3, and 7 days after the operation. The concentrations of plasma and intestinal CCK and the levels of mRNA of CCK in the intestinal mucosa and PSTIs in the pancreas were significantly increased by bile-pancreatic juice diversion. The increase in the mRNA level of PSTI-61 was significantly higher than that of PSTI-56. Administration of CCK antagonist inhibited these changes but administration of CCK agonist could not fully reproduce these changes. These studies suggest that bile-pancreatic juice regulates gene expression of CCK and PSTIs and that the regulatory mechanisms of gene expression of PSTI-61 and -56 may be different.

    Topics: Animals; Base Sequence; Bile; Biliopancreatic Diversion; Ceruletide; Cholecystokinin; Gastrointestinal Agents; Gene Expression; Hormone Antagonists; Infusions, Intravenous; Male; Molecular Sequence Data; Pancreas; Pancreatic Juice; Proglumide; Rats; Rats, Wistar; RNA, Messenger; Sincalide; Trypsin Inhibitor, Kazal Pancreatic

1995
Cholecystokinin [corrected] octapeptide modulates dopamine release in rat striatum.
    Neuroscience letters, 1995, Aug-11, Volume: 195, Issue:3

    The effect of cholecystokinin octapeptide sulfated (CCK8S) on the basal and electrically evoked release of [3H]dopamine ([3H]DA) in striatal slices from the rat brain was studied. Cholecystokinin octapeptide did not influence the basal release of [3H]DA. Field electrical stimulation (FES) (2 Hz) induced an increase of dopamine release from striatal slices, which was Ca2+ dependent and was abolished by tetrodotoxin, 10(-6) M. Cholecystokinin octapeptide (10(-9) M, 10(-8) M and 10(-7) M) dose dependently reduced the electrically evoked release of [3H]DA. This effect was antagonized by the CCK-A receptor antagonists loxiglumide (10(-7) M, 10(-6) M and 10(-5) M) or proglumide (10(-5) M, 10(-4) M and 10(-3) M). The results suggest that CCK receptors type A are involved in this effect of CCK8S in the striatum.

    Topics: Animals; Anti-Ulcer Agents; Apomorphine; Dopamine; Dopamine Agonists; Electric Stimulation; Hormone Antagonists; Male; Neostriatum; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide; Tritium

1995
Cholecystokinin-GABA interactions in rat striatum.
    Neuropeptides, 1995, Volume: 29, Issue:5

    The release of [3H]gamma-aminobutyric acid ([3H]GABA) from rat striatal slices before and during electrical field stimulation (EFS) was measured. Electrical stimulation (10 Hz) induced an increase of Ca(++)- and tetrodotoxin-sensitive [3H]GABA release from the striatal slices. In the presence of sulphated octapeptide of cholecystokinin, CCK-8S (10(-9) M, 10(-8) M and 10(-7) M) both the basal and the electrically (10 Hz)-evoked release of [3H]GABA were dose-dependently increased. These effects of CCK-8S were abolished by tetrodotoxin (10(-6) M) and were not influenced by the CCK-A receptor antagonist loxiglumide (CR1505) (10(-7) M and 10(-6) M). The stimulant effect of CCK-8S was antagonized by the newly synthesized CCK-B selective receptor antagonist PD134308 (10(-7) M and 10(-6) M). These findings suggest that CCK-8 plays a neuromodulatory role in the regulation of GABAergic neuronal activity in the striatum. The activation of CCK-B receptors located on GABAergic neurons is involved in the GABA release-potentiating effect of CCK-8S in rat striatum.

    Topics: Animals; Calcium; Cholecystokinin; Corpus Striatum; Electric Stimulation; gamma-Aminobutyric Acid; Hormone Antagonists; Indoles; Male; Meglumine; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide; Tetrodotoxin; Tritium

1995
Effect of gastrin-releasing peptide (GRP) on guinea pig gallbladder contraction in vitro.
    Journal of gastroenterology, 1995, Volume: 30, Issue:6

    Few studies have reported the effects of gastrin-releasing peptide (GRP)/bombesin on the guinea pig gallbladder, and the results are contradictory. Because such contradictory results may, in part, be due to technical factors, we investigated the effect of GRP on guinea pig gallbladder smooth muscle, using an improved horizontal organ bath. The guinea pigs were killed and the gallbladder was removed. Four longitudinal muscle strips (2 x 12 mm) were suspended in Krebs-Ringer solution at 37 degrees C and aerated with 95% O2 and 5% CO2. The mechanical activity of the strips was recorded isotonically by displacement-voltage transducers, via L-arms, to which a piezoelectric element with a frequency of 100 Hz and movement of 50 microns was applied. GRP contracted gallbladder muscle strips dose dependently, but the calculated maximal response was 22.4% and 20.1% of the acetylcholine- and cholecystokinin octapeptide (CCK8)-induced responses, respectively. The GRP-induced contraction was unaffected by the muscarinic blocker, atropine, or by the CCK receptor antagonist, loxiglumide. It is concluded that GRP weakly, but apparently directly, stimulates guinea pig gallbladder contraction.

    Topics: Acetylcholine; Animals; Atropine; Bombesin; Dose-Response Relationship, Drug; Gallbladder; Gastrin-Releasing Peptide; Guinea Pigs; Hormone Antagonists; In Vitro Techniques; Male; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Peptides; Proglumide; Sincalide

1995
Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 268, Issue:2

    The pharmacological profile of FK480[(S)-(+)-N-<1-(2)-fluorophenyl)-3,4,6,7-tetra hydro-4-oxo-pyrrolo(3,2,1-jk) (1,4)benzodiaze-pine-3-yl>-1H-indole-2- carboxamide], a novel cholecystokinin type-A (CCK-A) receptor antagonist, was compared with that of the CCK-A receptor antagonist, loxiglumide. Both FK480 and loxiglumide inhibited 125I-labeled CCK-8 (125I-CCK-8) binding to rat pancreatic and guinea-pig gallbladder membranes with IC50 values of 0.40 +/- 0.04 and 0.06 +/- 0.02 nM for FK480 and 330 +/- 66 and 66 +/- 10 nM for loxiglumide, respectively. These two agents also inhibited 125I-CCK-8 binding to guinea-pig brain (cerebral cortex) receptors with respective IC50 values of 72 +/- 11 nM and > 10 microM, indicating less affinity to central receptors. Intravenous administration of FK480 (ED50 = 18 micrograms/kg) was 2800 times more potent than that of loxiglumide (ED50 = 50 mg/kg) in inhibiting CCK-8-induced pancreatic amylase secretion in rats. Furthermore, FK480 had ED50 values of 10 and 8.4 micrograms/kg, respectively, in antagonizing CCK-8-induced inhibition of charcoal meal gastric emptying in mice when administered orally 1 or 5 hr before the CCK-8. Loxiglumide (ED50 = 23.5 mg/kg, when administered orally 1 hr before the CCK-8) also antagonized it, but its activity was 2400 times less than that of FK480. We conclude that FK480 is a potent, orally effective CCK-A receptor antagonist with long duration of action.

    Topics: Amylases; Animals; Benzodiazepinones; Female; Gastric Emptying; Guinea Pigs; Indoles; Male; Mice; Mice, Inbred ICR; Proglumide; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Sincalide

1994
Mechanisms for pancreatic hypertrophy induced by long-term administration of bethanechol.
    European journal of pharmacology, 1994, Nov-01, Volume: 292, Issue:1

    Mechanisms for the hypertrophy of rat pancreas induced by long-term administration of bethanechol were investigated. The administration of bethanechol, an acetylcholine receptor agonist, to male Wistar rats for 14 days induced significant increases in the pancreatic weight and contents of protein, amylase and RNA in the pancreas without altering the content of DNA and the incorporation of [3H]thymidine into DNA. Simultaneous administration of atropine with bethanechol suppressed the bethanechol-induced pancreatic hypertrophy. Long-term administration of other acetylcholine receptor agonists also showed similar effects as produced by bethanechol. CR1505 (loxiglumide; D,L-4-(3,4-dichlorobenzoyl-amino)-5-(N-3-methoxypropyl-pentylam ino)-5- oxopentanoic acid), an antagonist of cholecystokinin receptors, inhibited pancreatic growth induced by long-term administation of pentagastrin, whereas pancreatic hypertrophy induced by bethanechol was not inhibited by CR1505. These results suggest that long-term administration of bethanechol induces pancreatic hypertrophy through direct activation of muscarinic receptors in the pancreas.

    Topics: Amylases; Animals; Atropine; Bethanechol; Cholinergic Agonists; Cholinergic Antagonists; Drug Administration Schedule; Drug Interactions; Gastrins; Hypertrophy; Male; Organ Size; Pancreas; Pentagastrin; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide

1994
Inhibitory action of CCK-OP on rat proximal colon.
    Annals of the New York Academy of Sciences, 1994, Mar-23, Volume: 713

    Topics: Acetylcholine; Animals; Atropine; Colon; Fasting; Hexamethonium; Hexamethonium Compounds; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Proglumide; Rats; Receptors, Cholecystokinin; Sincalide

1994
Effect of intraduodenal infusion of tocamphyl on pancreatic exocrine secretion and gastrointestinal hormone release in rats.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1994, Volume: 15, Issue:3

    Tocamphyl is a synthetic choleretic that is derived from a root extract of Curcuma longa, L. We investigated the effect of tocamphyl on pancreatic exocrine secretion and bile flow, and on the release of some gastrointestinal hormones, by administering it intraduodenally using anesthetized rats. Tocamphyl stimulated pancreatic exocrine secretion in terms of volume and amylase output in a dose-related manner. Neither a CCK-receptor antagonist, CR1505 (loxiglumide), nor atropine sulfate infused intravenously suppressed the stimulatory effects of tocamphyl on pancreatic exocrine secretion and bile flow. The stimulatory effect on bile flow was stronger than that on pancreatic exocrine secretion. Plasma secretin levels were augmented with the increasing doses of tocamphyl, but CCK levels were not. These results indicate that intraduodenally administered tocamphyl stimulates pancreatic exocrine secretion and bile flow, and suggest that the stimulatory action is, at least in part, mediated by secretin, but not by either CCK or the cholinergic pathway.

    Topics: Analysis of Variance; Animals; Atropine; Bile; Camphor; Cholagogues and Choleretics; Cholecystokinin; Dose-Response Relationship, Drug; Drug Interactions; Ethanolamines; Gastrointestinal Hormones; Male; Pancreatic Juice; Proglumide; Radioimmunoassay; Rats; Rats, Wistar; Secretin; Sincalide

1994
Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
    Regulatory peptides, 1994, Jul-14, Volume: 52, Issue:2

    Pancreatic exocrine and endocrine function in postpancreatitic rats treated with cholecystokinin (CCK) receptor antagonist loxiglumide was compared with that treated with saline and CCK octapeptide (CCK-8) or with that in normal control rats. Treatment with loxiglumide (50 mg/kg body weight), CCK-8 (2.5 micrograms/kg body weight), or saline (2.5 ml/kg body weight) was given three times a day for 6 days starting 1 day after the induction of acute pancreatitis by a 4-h subcutaneous infusion of 20 micrograms/kg body weight/h of caerulein. On day 8, pancreatic exocrine and endocrine function was simultaneously determined following an intravenous injection of a mixed solution of 0.2 g/kg body weight glucose plus 100 ng/kg body weight caerulein. Basal pancreatic juice flow was significantly increased in all of the postpancreatitic rats irrespective of the treatment, whereas the maximal juice flow in the loxiglumide- and saline-treated rats was significantly low compared with the CCK-8-treated and the control rats. Basal and the peak protein outputs in the loxiglumide-treated rats were comparable to those in saline-treated rats, but were lower than those in the control or the CCK-8-treated rats. Although serum glucose concentrations in all of the postpancreatitic rats were similar to those in the control rats, stimulated as well as basal insulin release tended to be high compared with the control rats. In particular, loxiglumide-treated rats showed the exaggerated insulin response compared with other groups of rats. These present observations indicate that administration of high dose of loxiglumide for a long period decreases pancreatic enzyme output and causes insulin resistance.

    Topics: Acute Disease; Animals; Ceruletide; Glucose; Injections, Intravenous; Injections, Subcutaneous; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Pancreatitis; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide

1994
Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
    Pancreas, 1994, Volume: 9, Issue:3

    Biochemical and pharmacologic characteristics of a newly developed benzodiazepine derivative (S)-N-[1-(2-fluorophenyl)-3,4, 6,7-tetrahydro-4-oxo-pyrrolo-[3,2,1-jk] [1,4]benzodiazepine-3-yl]-1H-indole-2-carboxamide (FK480) as a cholecystokinin (CCK) receptor antagonist were examined in the isolated rat pancreatic acini and compared with those of MK-329 and loxiglumide. FK480, MK-329, and loxiglumide inhibited CCK octapeptide (CCK-8)-stimulated amylase release and binding of [125I]CCK-8 in a concentration-dependent manner, with a half-maximal inhibition (ID50) at 1.30 +/- 0.12 nM, 1.33 +/- 0.21 nM, and 1.27 +/- 0.23 microM, respectively, for amylase release, and 0.40 +/- 0.06 nM, 0.68 +/- 0.08 nM, and 0.38 +/- 0.03 microM, respectively, for [125I]CCK-8 binding. The antagonism was competitive in nature because these three compounds caused a parallel rightward shift of the dose-response curve for CCK-8-stimulated amylase secretion, without altering the maximal increase. The antagonism produced by FK480 was specific for CCK in that the effects of other receptor secretagogues or agents bypassing receptors were not altered. FK480 not only prevented but also reversed CCK-8-stimulated amylase release. This compound caused a residual inhibition of the action of CCK-8. When acini were preincubated with 100 nM FK480 for 30 min, the subsequent dose-response curve to CCK-8 was shifted 10-fold toward higher concentration. Similar results were obtained with MK-329 but not with loxiglumide. FK480 appeared to be bound to the receptors on acinar cells in a slowly dissociating state.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Animals; Benzodiazepinones; Devazepide; In Vitro Techniques; Indoles; Male; Pancreas; Proglumide; Rats; Rats, Wistar; Receptors, Cholecystokinin; Sincalide

1994
PD 135158, a CCKB/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist.
    European journal of pharmacology, 1993, Sep-21, Volume: 242, Issue:1

    The CCKB/gastrin receptor antagonist, PD 135158 (CAM 1028), surprisingly stimulates lipase release from isolated rat pancreatic acini dose dependently in a biphasic manner, with identical efficacy but lower potency compared to cholecystokinin octapeptide (CCK-8). Half-maximal stimulation occurred at 0.6 microM and maximal secretion was induced at 50 microM. Supramaximal concentrations decreased lipase release. Acinar lipase secretion in response to 25 pM CCK-8 or 1 microM CAM-1028 was abolished by 5 microM of the specific CCKA receptor antagonist loxiglumide (CR 1505), half-maximal inhibition was observed at 0.6 microM for CCK-8 and 0.4 microM for PD 135158. These data demonstrate that the CCKB/gastrin receptor antagonist, PD 135158, acts as a full agonist at the rat pancreatic CCKA receptor.

    Topics: Animals; Anti-Anxiety Agents; Cholecystokinin; Drug Interactions; Indoles; Lipase; Meglumine; Pancreas; Proglumide; Rats; Sincalide

1993
Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12

    Cholecystokinin is thought to be an important factor regulating the growth of human pancreatic cancers. The study was designed to evaluate the effects of the cholecystokinin antagonist loxiglumide (CR1505) on the growth of human pancreatic cancer.. Human gastrointestinal cancer xenografted tumors (one esophageal, one gastric, two colorectal, two biliary tract, and two pancreatic cancers) were transplanted into nude mice. The mice were given CR1505 at 250 mg/kg daily for 14 days, either subcutaneously or intragastrically, and the tumor volumes before and after treatment were compared. In vitro effects of CR1505 were assessed by measuring the DNA synthesis (3H-thymidine incorporation).. CR1505 inhibited the growth of the two pancreatic cancer lines but did not inhibit the growth of the other lines. CR1505 also inhibited in vitro DNA synthesis in the two pancreatic cancer lines at lower concentrations than in the other lines. This pancreatic cancer-specific inhibitory effect of CR1505 was retarded by exogenously administered cholecystokinin in one pancreatic cancer line but was augmented in the other line. The effect of CR1505 was inhibited by oral administration of the trypsin-inhibitor camostate (FOY-305) in both pancreatic cancer lines.. These results suggest that CR1505 may specifically inhibit the growth of human pancreatic cancers and may be suitable for clinical study. However, its antiproliferative effect may not necessarily be dependent on its cholecystokinin-antagonism but may be mediated through the proteolytic enzymes found in the lysosomes of the pancreatic cancer cells.

    Topics: Animals; Cell Division; Chloroquine; Cholecystokinin; DNA; Esters; Gabexate; Guanidines; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organ Culture Techniques; Pancreatic Neoplasms; Proglumide; Sincalide; Transplantation, Heterologous

1993
Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
    British journal of pharmacology, 1992, Volume: 106, Issue:1

    1. Interactions between cholecystokinin octapeptide (CCK-8) and CCKA-receptor antagonists derived from benzodiazepines (devazepide) and glutamic acid (lorglumide and loxiglumide) have been examined in an improved bioassay using the guinea-pig, isolated, gall bladder preparation. 2. The presence of CCKB-receptors in the assay was provisionally-ruled out on the basis of the low potency of pentagastrin in the assay. By applying analyses of both agonism and antagonism, pentagastrin was shown to behave as a partial agonist at the CCKA-receptor. 3. Devazepide, lorglumide and loxiglumide behaved as simple competitive antagonists of CCKA-receptors and pKB values of 9.98, 7.59 and 7.07 were estimated, respectively. 4. Application of a combined dose-ratio analysis to the interactions between CCK-8 and combinations of devazepide/lorglumide and devazepide/loxiglumide indicated that these molecules behave as syntopic, competitive, antagonists at the CCKA-receptor. 5. We conclude that the guinea-pig gall bladder assay contains a homogeneous population of CCKA-receptors and offer an explanation for the differences between our results and those obtained recently by Maubach et al. (1991) which were taken as preliminary evidence for CCKA-receptor heterogeneity.

    Topics: Analysis of Variance; Animals; Benzodiazepinones; Binding, Competitive; Biological Assay; Cholecystokinin; Devazepide; Dose-Response Relationship, Drug; Gallbladder; Guinea Pigs; Muscle, Smooth; Pentagastrin; Proglumide; Receptors, Cholecystokinin; Sincalide

1992
Cholecystokinin contracts isolated human and monkey iris sphincters; a study with CCK receptor antagonists.
    European journal of pharmacology, 1992, Feb-11, Volume: 211, Issue:2

    The contractile effects of cholecystokinin (CCK) on iris sphincter and ciliary muscles from monkey and human eyes were studied using an isolated smooth muscle bath. The ability of the CCKA receptor antagonists, lorglumide and loxiglumide, to inhibit CCK-8s-induced contraction was also examined. Various neuropeptides reported to be present in capsaicin-sensitive sensory neurons were also screened for contractile effect. CCK contracted isolated human and monkey iris sphincters at nM concentrations. Both antagonists caused a rightward shift of the dose-response curve for CCK-8s on the monkey iris sphincter. The ciliary muscle from both species failed to contract in response to CCK-8s. Of the eight other neuropeptides screened on the monkey iris sphincter, only [Arg8]vasopressin elicited a weak contraction when used in microM concentrations. These results indicate that the primate iridial sphincter muscle exhibits a high sensitivity to CCK, and that CCKA receptor antagonists effectively block the CCK-induced contraction.

    Topics: Aged; Aged, 80 and over; Animals; Cholecystokinin; Female; Humans; In Vitro Techniques; Iris; Macaca fascicularis; Male; Middle Aged; Muscle Contraction; Proglumide; Receptors, Cholecystokinin; Sincalide

1992
Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.
    British journal of pharmacology, 1991, Volume: 102, Issue:2

    1. Three recently described non-peptide cholecystokinin (CCK) antagonists (devazepide, lorglumide, loxiglumide) have been studied for their antagonism of the contraction to cholecystokinin-octapeptide (CCK-OP) in human alimentary muscle and guinea-pig intestine. 2. Each antagonist caused a concentration-dependent inhibition of the contraction induced by CCK-OP, regardless of regional and species differences. 3. The potencies of each drug, estimated by use of an adaptation of the Cheng & Prusoff equation, were similar in the different regions of human alimentary tract (weighted mean apparent pKB, +/- s.e. mean: devazepide, 5.76 +/- 0.08, n = 20; lorglumide, 5.82 +/- 0.04, n = 25; loxiglumide, 5.87 +/- 0.07, n = 24). 4. In contrast, the potencies differed markedly in the guinea-pig ileum. Apparent pKB values obtained by the same method as with human tissues were, mean +/- s.e.mean: devazepide, 10.61 +/- 0.61; lorglumide, 7.43 +/- 0.20; loxiglumide, 6.67 +/- 0.12. pKB values obtained from classical competition experiments were: devazepide, 10.09 +/- 0.09; lorglumide 7.70 +/- 0.12; loxiglumide 6.08 +/- 0.22. 5. The CCK receptors in human gut muscle from different regions seem to be similar, but there appear to be species differences.

    Topics: Animals; Benzodiazepinones; Cholecystokinin; Devazepide; Digestive System; Digestive System Physiological Phenomena; Female; Guinea Pigs; Humans; Ileum; In Vitro Techniques; Male; Muscle Contraction; Proglumide; Receptors, Cholecystokinin; Sincalide

1991
Mechanism of inhibitory action of peptide YY on cholecystokinin-induced contractions of isolated dog ileum.
    Regulatory peptides, 1990, Feb-04, Volume: 27, Issue:2

    In isolated canine ileal longitudinal muscle preparations, cholecystokinin-octapeptide (CCK-8) produced a concentration-dependent contraction, which was suppressed by peptide YY (PYY) and was abolished by tetrodotoxin and atropine. PYY was approximately 2200-times as potent as CR1505, a CCK-receptor antagonist. PYY opposed the action of CCK-8 to a greater extent than that of nicotine and transmural electrical stimulation. Acetylcholine-induced contractions were not influenced by PYY. It seems likely that the CCK-8-induced ileal muscle contraction is associated with an activation of CCK receptors in cholinergic nerves, which generates nerve action potentials and releases acetylcholine, whereas CCK-8 acts on CCK receptors in gallbladder smooth muscle, producing contractions. It may be concluded that PYY inhibits the action of CCK-8 on ileal muscle strips, by inhibiting the release of acetylcholine from cholinergic nerve terminals. On the other hand, in the gallbladder, PYY does not appear to block cholinergic nerve function.

    Topics: Animals; Cholecystokinin; Dogs; Female; Gallbladder; Glutamine; Ileum; Isometric Contraction; Male; Muscle Contraction; Peptide YY; Peptides; Proglumide; Sincalide

1990
Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
    Digestive diseases and sciences, 1989, Volume: 34, Issue:6

    D,L-4-(3,4-dichlorobenzoylamino)-5-(N-3-methoxypropyl-pentylami no)-5- oxopentanoic acid (CR 1505; loxiglumide) is a newly developed analog of proglumide. We examined the inhibitory effects of loxiglumide on pancreatic exocrine function in the isolated pancreatic acini and the isolated perfused pancreata of rats. Loxiglumide inhibited cholecystokinin octapeptide (CCK-8)-stimulated amylase release and, similarly, binding of [125I]CCK-8 to isolated rat pancreatic acini. Loxiglumide was about 3000 times more potent than the reference substance proglumide, but was about 1000 times less potent than L-364,718, another new CCK antagonist having benzodiazepine ring, in inhibiting CCK-8-stimulated amylase release. The inhibitory effect of loxiglumide displayed competitive kinetics and was specific for CCK in that the effects of other receptor secretagogues or agents bypassing receptors were not altered. The inhibitory effect of loxiglumide was fully reversible in isolated acini. However, the pancreata perfused with 10 microM loxiglumide for 20 min did not respond to CCK-8 for more than 20 min even after the removal of loxiglumide infusion. In contrast, an immediate increase in pancreatic exocrine secretion was observed after proglumide removal. Loxiglumide appeared to be bound to the receptors on acinar cells in a slowly dissociating state. These results indicate that loxiglumide acts as a potent, competitive, and specific CCK antagonist on the exocrine pancreas and, because of its prolonged inhibitory action, may be useful as a therapeutic agent in pancreatic disease.

    Topics: Amylases; Animals; Binding, Competitive; Cholecystokinin; Dose-Response Relationship, Drug; Glutamine; Pancreas; Proglumide; Rats; Receptors, Cholecystokinin; Sincalide

1989
[Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1989, Volume: 86, Issue:1

    The effect of a new proglumide derivative, loxiglumide (DL-4-(3,4-dichloro-benzoyl-amino)-5-(N-3-methoxy-propyl-pentylamino+ ++)-5-oxo-pentanic acid; CR 1505), on binding of 125I-CCK-8 and amylase release stimulated by CCK-8 was investigated in isolated rat pancreatic acini. Loxiglumide inhibited CCK-8-stimulated amylase release and binding of 125I-CCK-8 to rat pancreatic acini in a dose-dependent manner. Loxiglumide caused a concentration-dependent rightward shift of the dose-response curve for CCK-8-stimulated amylase release without altering the maximal response. Schild plots showed a slope of 0.82 and pA2 value of 7.05. The inhibitory effect of loxiglumide on amylase release was reversible. Loxiglumide significantly inhibited amylase release in response to CCK-8, caerulein and gastrin-I. However, loxiglumide had no effect on amylase release stimulated by other receptor secretagogues (bombesin, carbamylcholine, secretion and vasoactive intestinal polypeptide) or by agents bypassing receptors (A23187 and TPA). These results indicate that loxiglumide acts as a potent, competitive and specific CCK antagonist on the pancreatic acini.

    Topics: Amylases; Animals; Cholecystokinin; Glutamine; In Vitro Techniques; Male; Pancreas; Proglumide; Rats; Rats, Inbred Strains; Sincalide

1989
CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man.
    Gut, 1989, Volume: 30, Issue:8

    The postprandial contractions of the gall bladder result from the interaction of neurohormonal factors but their relative contribution is unknown. This study was designed to determine the role of cholecystokinin (CCK) in gall bladder contractions using a highly selective and potent CCK-receptor antagonist, CR-1505 (loxiglumide) in healthy men either infused with exogenous CCK in graded doses (1.56-50 pmol/kg/h) or subjected to modified sham feeding (MSF) and ordinary feeding tests. The gall bladder volume measured by real time ultrasonography showed dose dependent decrease in the gall bladder volume in 10 subjects when CCK8 was infused iv in graded doses reaching about 15% at 1.56 pmol/kg/h and 91% at 50 pmol/kg/h. Close correlation between the decrease in gall bladder volume and the dosage of CCK or the increments in plasma CCK-bioactivity was observed. After pretreatment with loxiglumide, CCK resulted in similar increments in plasma CCK-bioactivity but failed to affect the gall bladder volume at CCK doses up to 6.25 pmol/kg/h and caused only 53% reduction at 50 pmol/kg/h. Modified sham feeding and real feeding reduced the volume of gall bladder by 20% and 70%, respectively and loxiglumide decreased these values to 15% and 30%, respectively. This study provides evidence that loxiglumide is highly potent and selective CCK antagonist and that endogenous CCK plays an important role both in the postprandial contractions of gall bladder.

    Topics: Adolescent; Adult; Cholecystokinin; Food; Gallbladder; Glutamine; Humans; Male; Muscle Contraction; Proglumide; Receptors, Cholecystokinin; Sincalide

1989
Biological effects of a proglumide derivative as cholecystokinin antagonist in conscious dogs.
    Regulatory peptides, 1987, Aug-17, Volume: 18, Issue:3-4

    In conscious dogs we studied the effects of a new cholecystokinin (CCK) antagonist (coded CR 1505) on CCK8-stimulated exocrine pancreatic secretion and release of pancreatic polypeptide (PP). Graded doses of CCK8 (25-400 ng kg-1h-1) were infused i.v. Experiments were repeated against a background infusion of CR 1505 at different doses (0.1, 1 and 10 mg kg-1h-1). The lowest dose of CR 1505 had no biological effects. However, at the upper two doses the compound significantly inhibited the CCK8-stimulated PP release. Furthermore, a significant inhibition of exocrine pancreatic protein secretion was observed with 10 mg kg-1h-1 of CR 1505 (P less than 0.05). The results suggest that CR 1505 could be a useful tool in defining the physiological role of CCK in vivo.

    Topics: Animals; Cholecystokinin; Dogs; Dose-Response Relationship, Drug; Gastric Acid; Glutamine; Infusions, Intravenous; Pancreatic Juice; Pancreatic Polypeptide; Pentagastrin; Proglumide; Sincalide

1987